You searched for: primary outcome measure (Engelska - Slovenska)

outcome measure
merilo izida

the primary efficacy outcome measure was os.
primarno merilo izida učinkovitosti je bilo celokupno preživetje.

confirmation; primary outcome)
tednih; primarni izid)

the primary outcome measure was overall survival (os).
primarno merilo izida je bilo celokupno preživetje (os, overall survival).

outcome measure compared to baseline
merilo izida v primerjavi z izhodiščno vrednostjo

the primary efficacy outcome measure was overall survival (os).
primarno merilo izida učinkovitosti je bilo celokupno preživetje (os - overall survival).

for both studies, the primary outcome was based on relapse.
v obeh študijah je bil primarni cilj opazovanja relaps.

the primary outcome measure was overall survival defined as the time from randomisation until death from any cause.
primarni cilj preskušanja je bilo celokupno preživetje, definirano kot čas od randomizacije do smrti iz kateregakoli vzroka.

the co-primary outcome measures were progression-free survival and os.
primarni merili učinkovitosti sta bili preživetje brez napredovanja bolezni in celokupno preživetje (os).

1 primary and secondary outcome of double-blind trial primary outcome
primarni in sekundarni izidi dvojno slepega preskušanja primarni izidi

the primary outcome assessment was the reduction in “off” time (hours).
primarna ocena izida je bilo zmanjšanje časa »izklop« (v urah).

the data from the primary outcome parameter, change in fev1 % predicted, are not normally distributed.
podatki parametrov primarnega dogodka, sprememba napovedanih odstotkov fev1, niso normalno porazdeljeni.

the primary efficacy outcome measures were pfs as assessed by iro using recist version 1.1 and os.
primarni merili izida učinkovitosti sta bili preživetje brez napredovanja bolezni, ocenjeno po iro na podlagi meril recist, različica 1.1, ter celokupno preživetje.

the primary outcome measure was the weekly mean of 24-hour average pain, which was collected in a daily diary by patients on an 11-point likert scale.
primarna mera izida je bilo tedensko povprečje 24-urne povprečne bolečine, kar smo zbrali iz dnevnih dnevnikov bolnikov na podlagi 11- točkovne likertove lestvice.

the primary outcome was the proportion of patients with a 1 or more hour increase in on time (see table 1).
primarni izid je bilo razmerje bolnikov z eno - ali večurnim povečanjema vključitvenega (on time) obdobja (glejte preglednico 1).

secondary efficacy outcome measures were orr and response duration.
sekundarni merili izida učinkovitosti sta bili celokupni delež odgovora in trajanje odgovora.

additional outcome measures included duration and timing of response.
dodatna merila izida so vključevala trajanje in čas pojava odziva.

key outcome measures from brighter and crystal are shown in table 5.
glavni izidi meritev v študijah brighter in crystal so prikazana v preglednici 5.

adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure, cgi-bp severity of illness score (mania).
dodatno zdravljenje z aripiprazolom se je izkazalo za boljše od placeba tudi pri sekundarnem merilu izida, lestvici resnosti bolezni cgi-bp za manijo.

xeristar 60 mg once daily demonstrated a statistically significant superiority compared to placebo (p=0.004) on the primary outcome measure, the prevention of depressive relapse, as measured by time to relapse.
zdravljenje z zdravilom xeristar 60 mg enkrat na dan se je izkazalo za statistično značilno boljše v primerjavi s placebom (p = 0,004) pri merilu primarnega izida, preprečevanju relapsa depresije, kot so izmerili s časom do relapsa.